 After their written informed consent has been obtained and their eligibility verified, patients are randomised between 4 treatment arms: A1 VAD 4 cycles; A2 VAD 4 cycles followed by DCEP 2 cycles; B1 Velcade dexamethasone 4 cycles; B2 Velcade dexamethasone 4 cycles followed by DCEP 2 cycles A1, A2, B1, B2 autograft. Randomisation will be stratified on the basis of the initial b2 microglobulin level or 3 mgl and the presence of chromosome 13 abnormalities identified by FISH analysis. VAD: VincristineAdriamycinDexamethasone; DCEP: DexamethasoneCyclophosphamide EtoposideCisplatin. 